initi buy earli pipelin bolster
see momentum first-in-human data lead asset
immuno-oncolog asthma respect co
robust discoveri platform center anticalin protein management
leverag ink multipl high-profil partnership pipelin matur
expect influx clinical-stag asset drive valu next sever
year initi buy pt
joint-book run manag secondari offer februari
like uptak therapi across multipl tumor
type like bispecif mechan local cancer cell
costimul t-cell tumor microenviron preclin research show
good affinity/specif well efficaci safeti signal anim mitig
commerci opportun gastric bladder breast cancer w/ add upsid gain
approv tumor type and/or advanc forward line therapi sign earli
efficaci pi expans cohort readout could drive share
entri sever asthma compel given conveni daili dose
thru inhal similar ics/laba combo target approach
similar biolog valid dupi think option formul
singl combo product provid price flexibl value-add payer
perspect right price point could captur market share inhal well
biolog agent top-line safeti data pi trial catalyst stock
pharma partnership showcas management savvi help valid anticalin
platform given rel earli pipelin number collabor servier
azn aska sw secur management impress deal provid extern
valid underli anticalin tech provid versatil mab w/
smaller size confer greater formul stabil also allow
engin multi-specif function
pt dcf-base contribut provid
remain cash risk includ clinic manufactur competit regulatori
pleas see analyst certif import disclosur inform inform regard statu non-u analyst page report
model us peak sale risk-adj
appli risk discount across indic
model us peak sale risk-adj eu peak sale
risk-adjust asthma appli risk
discount
model risk-adj royalti astrazeneca
approv solid cancer gastric
bladder breast us
approv sever uncontrol asthma us
eu
us market approv trigger mileston
payment astrazeneca pieri
pieri opt us eu commerci
pieri time peak sale
astrazeneca receiv tier royalti
expect pieri receiv mileston payment
astrazeneca upon us market approv
report initi safeti pk/pd data pi trial prs-
gastric cancer fulli derisk price
solid cancer
bladder cancer fulli derisk price
begin expans phase local advanc
metastat solid cancer gastric bladder breast
report initi safeti pk/pd data pi trial prs-
breast cancer fulli derisk price
healthi volunt
report top-line data piia trial
sever uncontrol asthma fulli derisk
initi program addit respiratori target within
develop unsuccess gastric
develop unsuccess bladder
develop unsuccess breast
develop unsuccess sever
page
pleas see import disclosur inform page report
inc clinical-stag biotechnolog compani
engag discoveri develop anticalin protein-bas drug
direct valid therapeut target diseas pathway
use proprietari platform engin produc anticalin
yield sever product pi/ii develop first novel
bispecif antibodi compos trastuzumab variant mab
fuse anticalin specif immun receptor immuno-oncolog
agent applic varieti advanc cancer includ
gastric bladder breast sizabl combin market opportun
preclin data show strong efficaci bridg mechan
cancer cell stimul cytotox t-cell
tumor microenviron second pure anticalin protein
develop treatment sever asthma target well-
valid target key advantag formul stabl dri
powder inhal would repres first-in-class target
biolog direct pulmonari deliveri asthma think could
disrupt term tradit distinct low-cost non-
target ics/laba combo inhal premium-pr target biolog
administ sc iv third pegyl anticalin design
inhibit hepcidin neg regul iron absorption/storag
contribut function iron defici chronic kidney diseas
expect first-in-human data pi trial serv
catalyst could also see result piia trial although
pipelin earli encourag focu develop
treatment valid target well numer partnership
servier azn sw aska help valid anticalin platform
provid opportun mileston payment initi buy
pt
coupl valid target multipl oncolog indic
promis io mechan largest opportun pipelin
deriv address cancer popul anim
studi bispecif show superior efficaci mab
singl function avoid liver toxic seen competitor
mab bmi urelumab preclin clinic studi
date total address cancer market depend number
cancer type obtain approv line therapi
achiev think could get uptak therapi multipl
cancer includ gastric bladder breast valuat
bladder provid largest singl indic opportun although
numer market therapi proven clinic valu
continu inhibit progress trastuzumab drive need
express cell line could potenti broaden address
popul beyond standard differenti exist therapi
 aspir goal label expans look result expect
pi expans cohort patient advanc cancer
earli signal efficaci
provid differenti entri first inhal biolog
sever asthma think right attribut see good
uptak claim respect market share highli competit asthma
page
pleas see import disclosur inform page report
market term formul inhal deliveri give drug
conveni inhal agent asthma patient familiar
moreov daili dose allow option combin
therapi mainstay asthma best repres wide use ics/laba
combo major driver inflammatori pathway
valid target atop dermat asthma regn hold
dupilumab dupix make ration target expect
command premium ics/laba combo predict list
price significantli less current sc/iv biolog asthma thu
avoid oner payer restrict differenti favor would
clean toxic profil given ics/laba combo long-standing safeti
concern laba compon efficaci patient moder
eosinophil count sinc current crop biolog show disproportion
benefit mainli patient eosinophils/mcl await first data
on-going pi trial expect get earli read safeti gaug
long-term prospect
preclinical-stag asset provid addit upsid
differenti use anticalin backbon drug candid
configur pure anticalin protein complex
fusion protein one modal near-term
challeng compani alloc resourc given
multipl asset enter close clinic develop think compani
choos advanc ahead option due
market opportun wholli own preclinical/discoveri
pipelin includ bispecif antibodi
seri io candid repres addit upsid valuat
collabor seattl genet servier astrazeneca roch aska
cover program repres up-front payment
biobuck conting mileston big pharma partnership
provid extern valid anticalin technolog success
mileston de-risk platform
valu inc assum market entri
treatment advanc gastric bladder breast
cancer estim us total peak sale approxim risk-adjust
across indic
regard expect us launch partner astrazeneca assum market
entri treatment sever uncontrol asthma estim ww peak
sale approxim risk-adjust sever uncontrol
asthma assum risk discount assum pieri opt us
commerci astrazeneca model tier royalti us sale
estim total royalti risk-adjust astrazeneca pieri peak sale
model eu launch present includ
anemia immuno-oncolog indic valuat asset
repres addit upsid estim arriv price target base
discount cash flow valuat model assum wacc termin growth
rate outstand share million exhibit
page
pleas see import disclosur inform page report
biotechnolog pharmaceut
clinic failur compani
develop treatment futur clinic failur on-going clinic trial may
impact estim
regulatori failur fda and/or ema may delay approv compani
investig target delay approv could lead chang estim price
commerci risk delay market entri chang reimburs and/or potenti
competit threat could lead us revis estim price target and/or rate
competit risk compani develop treatment variou stage
clinic develop compet compani clinical-stag asset
product candid superior therapeut profil approv
compani product marketplac even approv could advers impact
financ risk compani may need rais addit fund support sg
 activ
headquart
boston massachusett pieri
pharmaceut inc clinical-stag biotechnolog compani center
proprietari anticalin technolog platform develop anticalin protein-bas drug
candid address high-unmet medic need cancer respiratori diseas
therapeut area compani lead asset anticalin-bas
bispecif antibodi target treatment cancer
inhal anticalin protein target treatment sever asthma
pegyl anticalin target hepcidin treatment function iron
defici chronic kidney diseas compani complet pipelin partnership
exhibit upcom catalyst exhibit depict follow
page
pleas see import disclosur inform page report
exhibit pipelin partnership
page
pleas see import disclosur inform page report
candidatetarget indic phase commerci rightswholli own bispecif immuno-oncolog posit solid cancer gastric bladder breast uterine/endometri programsn /n bispecif immuno-oncologydiscoveryu programn immuno-oncologydiscoverymileston uncontrol asthmapiu programsn respiratori diseasespiu pi mad escal trial cancer initi safeti pk/pd data pi expans phase local advanc solid cancer gastric bladder pi trial healthi initi safeti pk/pd data pi top-line data piia trial fid anemia program addit respiratori target allianc
cancer
rational preclin data
incorpor bispecif target approach drive
t-cell respons cancer lead immuno-oncolog asset prs-
bispecif antibodi dualli target tumor protein neu
anticalin protein specif genet fuse variant
monoclon antibodi trastuzumab bind receptor overexpress tumor
cell mechan action involv bridg activ t-cell
tumor cell local fashion within tumor microenviron aim
increas efficaci decreas system toxic exhibit aspect
bispecif select well-valid target overexpress numer
cancer long track record success target differ
drug conjug ado-trastuzumab emtansin small molecul lapatinib
select aspect primarili reli role key costimulatori signal
activ t-cell though also express immun cell
t-cell b-cell nk cell dendrit cell importantli signal critic
t-cell expans prevent t-cell exhaust induct anti-tumor cytotox
activ memori t-cell differenti need durabl respons
exhibit rational mechan
show potent costimulatori t-cell activ presenc
cell leverag human anticalin protein lipocalin also
known neutrophil gelatinanse-associ lipocalin ngal creat aspect
bispecif lipocalin bind pocket redesign specif point mutat
gener librari construct could screen affin select
construct bound human affin nm confirm
surfac plasmon reson bind assay could costimul human t-cell cell-
base assay ad togeth t-cell coreceptor antibodi anticalin
genet fuse trastuzumab mab variant
flexibl acid linker sequenc creat final bispecif antibodi
page
pleas see import disclosur inform page report
anticalin protein connect trastuzumab variant sever configur n-
c-termin heavi light chain via flexibl acid linker gener sever
bispecif candid candid test individu sandwich elisa
assay abil bind target briefli cell cultur plate coat
recombin bispecif candid allow bind ligand
detect tag introduc variou candid anticalin protein join
c-termin heavi chain trastuzumab variant candid produc
robust signal elisa assay indic configur possess optim
rigor test mechan gener report cell assay base
sandwich elisa principl confirm bind translat t-cell activ
first high gastric cancer cell incub
jurkat cell immort t-lymphocyt cell line carri nf-kb luciferas
report ad recal nf-kb known downstream signal target
signal nf-kb report detect presenc cell jurkat t-
cell neg control cell omit trastuzumab
substitut gener signal confirm bispecif engag
target t-cell activ exhibit left panel anoth variat cell-
base assay t-cell activ measur secret cytokin level induc
ifn-i dose-depend manner exhibit right panel
exhibit valid preclin cell-bas assay
mechan translat anti-tumor efficaci control t-cell
expans anim model anim studi bispecif function
demonstr superior inhibit tumor growth compar agonist
activ mab immunocompromis mice engraft human tumor
cell treat weekli dose neg control ug ug prs-
mab treatment either dose result smaller median
final tumor volum compar mab neg
control day treatment exhibit left panel moreov
tumor recov immunostain human leukocyt common
antigen marker tumor-infiltr lymphocyt til high dose
show median cell within tumor compar less
page
pleas see import disclosur inform page report
treatment group indic increas til infiltr exhibit right panel
interestingli low dose still exhibit robust tumor growth inhibit
though somewhat less high dose despit elicit til infiltr
investig hypothes low-dos could still exert anti-tumor efficaci
pure antagon akin effect trastuzumab alon
studi durat day kol feedback suggest
efficaci could persist much longer recent kol event februari
preclin mous model show one-tim costimul confer protect
t-cell memori year face tumor rechalleng everi day paper
bartkowiak colleagu show combo hpv vaccin agonist
prevent hpv tumor recurr day includ one tumor rechalleng
day wherea hpv vaccin alon saw rapid regrowth aggress tumor within
day bartkowiak et al pna addit t-cell costimul
uniqu phenotyp associ high level eomesodermin transcript
factor curran et al activ t-cell eosmesodermin gene
signatur possess enhanc cytotox well stem cell memori allow
rapid respons initi recurr tumor final uniqu t-cell express
high level anti-apoptot protein bcl allow cell surviv hypox tumor
exhibit efficaci mous model cancer
safeti superior toxic profil comparison mab
show acceler mortal due acut graft vs host diseas begin day
post-treat exhibit left panel phenotyp peripher blood
mononuclear cell day indic mab elicit
cell cell comparison variou dose elicit
cell cell exhibit right panel rel basi
data suggest lead control expans t-cell less
exposur system circul
issu peripher toxic plagu clinic develop
mab bristol myer squibb hold cover ian hillik urelumab
recent safeti analysi integr find sever trial urelumab advanc
solid cancer show signific hepat toxic grade elev ast alt
page
pleas see import disclosur inform page report
bilirubin occur patient dose mg/kg segal et al clin
cancer wherea dose mg/kg less like associ sever
liver toxic death due hepat failur record dose mg/kg
mg/kg respect patient receiv mg/kg discontinu
treatment due treatment-rel advers event interestingli hepat inflamm
agonist found even preclin model thought
associ product activ myeloid lineag cell infiltr liver
curran et al second agonist utomilumab
develop buy design avoid hepatotox
antibodi focus bind epitop within region wherea urelumab
bound epitop within bind region furthermor antibodi compet
ligand wherea urelumab antibodi avoid
liver toxic seen w/ urelumab hasnt quit exhibit strong efficaci profil
view differenti competitor mab efficaci given
target agent safeti sinc compon like activ
tumor microenviro vs peripheri
exhibit safeti mous model cancer
expect clinic develop
valu proposit rest demonstr efficaci across multipl
tumor type recal conduct pi open-label multiple-ascend
dose escal trial adult follow expans
cohort addit patient unresectable/loc advanc metastat
tumor compani plan focu patient gastric
bladder breast cancer expans cohort patient solid
tumor uterine/endometri ovarian biliari nsclc esophag colorect
cervic cancer could also enrol safeti profil maximum toler dose
recommend dose dose schedul extract result earli
efficaci signal could guid priorit develop among differ cancer type
valu proposit requir address unmet need across numer
cancer total address market becom substanti account
gastric bladder breast sever type us potenti eu howev
page
pleas see import disclosur inform page report
uptak exist therapi across differ cancer vari wide term
patient popul line therapi heterogen stem tumor type-specif
differ efficaci well total number competitor indic go
forward critic clinic trial demonstr efficaci
better understand avail opportun determin
address us market sever cancer process identifi
like point-of-entri given current treatment paradigm cancer
exhibit assumpt clinic develop base
tumor composit on-going pi trial accord analysi opportun
present bladder cancer largest due higher overal preval
diseas well higher posit rate compar cancer type howev
note potenti headwind given therapi approv
bladder cancer trial involv agent post mix result date
furthermor inhibit shown recent success set lead
approv five checkpoint inhibitor bladder cancer progress platinum-bas
chemotherapi gastric cancer
lower preval still present sizabl
opportun sinc therapi better valid cancer type
greater potenti achiev usag follow trastuzumab lastli breast
cancer present smaller nich opportun due well-entrench agent
proven robust efficaci set exhibit
exhibit us market opportun potenti points-of-entri treatment paradigm
could provid mean effect treat select
patient broaden address popul accord nccn guidelin
breast gastric cancer therapi initi patient
tumor sampl test immunohistochemistri pair
fluoresc situ hybrid fish -posit sampl read
pair fish-neg interpret current
consensu criteria assess breast cancer endors asco/cap
page
pleas see import disclosur inform page report
cancer typepreval us pt w/ advanc diseas expect therapi therapi size address patient us gastric cancerbladd cancerbreast cancerddmvac dose-depend methotrex vinblastin doxorubicin cisplatinind like point-of-entri type therapi advanc diseasepertuzumab trastuzumab docetaxelado-trastuzumab emtansinelapatinib capecitabin combo regimensecond- cisplatin/fluoropyrimidinetaxan /-ramucirumabnon specifiedgemcitabin cisplatin ddmvac growth factor inhibitortaxan includ nab-paclitaxel pemetrex platinum first-
present exhibit assess gastric cancer gener align minor
differ stain pattern guidelin updat
sever protocol chang includ revis cutoff level intens
complet membran stain requir tumor cell vs previous
fish-posit ratio requir posit vs previous
function chang result relax criteria posit readout
express hypothes potenti expand usag
therapi fan colleagu analyz equivoc case institut
revis guidelin well older guidelin determin
whether substanti chang classif new guidelin
investig found case previous score
reclassifi thu elig treatment agent fan et al
spectrum without clear breakpoint minor chang consensu criteria
substanti alter address popul
exhibit asco/cap consensu criteria assesss breast cancer
convent wisdom hold neg patient fish-
neg treat therapi sinc likelihood
obtain meaning clinic respons low gener accept
case would concord neg fish signal though reflex fish test
actual perform case howev note sever report literatur
select breast cancer case aggress featur high-grad
underw fish test found posit express sampl
breast cancer case meet criteria posit fish
result iorfada et al ann oncol anoth studi breast cancer case
similarli select fish-posit petroni et al oncol lett
author suggest extend fish screen tumor display aggress
featur cost-effect way captur patient would
otherwis miss alon
page
pleas see import disclosur inform page report
ihcscorestain membran stain incomplet stain faint/bar percept cancer membran stain faint/bar percept cancer membran stain complet intens cancer cellspositivenonenapositiveihc immunohistochemistri fish fluoresc situ hybridizationfish assayfishstatuspositiveequivoc negativepositivepositiveequivoc neg equivoc fish statu requir dual probe test retest use singl probe retest use dual ratio ratio averag copi number ratio averag copi number ratio averag copi number signals/cellsingl probedu probefish signalaverag copi number signals/cellaverag copi number signals/cellaverag copi number membran stain incomplet and/or weak/moder cancer cell circumferenti stain complet intens cancer cellsequivocalfish assay
kol feedback indic preclin data show efficaci cell line
consid rais possibl address popul futur
trial plan adher standard asco/cap guidelin
fish-posit enrol proof-of-concept trial possibl later stage trial
could includ care select patient subgroup analysi could
differenti approv agent second function target
permit cytotox t-cell infiltr tumor target cancer cell rel lower
advanc gastric cancer present opportun novel
target agent therapi piii toga trial establish benefit ad
trastuzumab cisplatin fluoropyrimidin regimen advanc gastric
cancer bang et al lancet trastuzumab plu chemotherapi accept
standard-of-car therapi unresect local advanc recurr metastat
gastric cancer nccn guidelin patient progress trastuzumab plu
chemotherapi nccn guidelin recommend switch taxane-bas regimen /-
ramucirumab cymraza numer trial assess later gener
target agent none asid trastuzumab abl demonstr
signific benefit either leav field wide open entri second
agent could see slot treatment landscap
gastric cancer trastuzumab failur
recent piii jacob trial attempt replic dual benefit
trastuzumab pertuzumab plu chemotherapi seen semin piii cleopatra
trial metastat breast cancer jacob trial patient metastat
gastric gastroesophag junction cancer random receiv triplet
trastuzumab pertuzumab chemotherapi doublet trastuzumab plu
chemotherapi therapi result present esmo addit pertuzumab
narrowli fail show statist signific chang primari endpoint
similarli secondari endpoint fail hit statist signific
addit pertuzumab mo experiment arm vs mo standard care arm
hr neg outcom surpris studi adequ
power enrol highli express patient fish-
posit taberno et al present esmo congress
set pii/iii gatsbi trial investig use ado-trastuzumab emtansin
advanc gastric cancer patient progress frontlin therapi
studi util two-stag design first stage consist dose optim
among two differ schedul ado-trastuzumab emtansin vs physician choic
taxan chemotherapi docetaxel paclitaxel second stage select schedul
ado-trastuzumab emtansin weekli compar docetaxel
paclitaxel weekli pool taxan patient final analysi median os
month ado-trastuzumab emtansin vs month taxan chemotherapi
indic miss primari endpoint hr numer
inferior perform standard-of-car therapi thuss-pati et al lancet
page
pleas see import disclosur inform page report
anoth studi piii tytan trial examin use lapatinib advanc gastric
cancer patient across five asian countri two-stag design util
dose optim follow random phase fish-posit patient
receiv lapatinib daili plu paclitaxel weekli paclitaxel alon
interestingli patient receiv previou trastuzumab therapi effect
present therapy-nav popul primari endpoint median os
lapatinib plu paclitaxel achiev month vs month paclitaxel alon
non-statist signific improv furthermor differ
secondari endpoint vs mo time progress vs mo
experiment vs standard treatment arm respect also deem non-signific
asid therapi agent make inroad treatment
advanc gastric cancer pembrolizumab keytruda investig
keynot piii keynot trial patient
progress frontlin chemotherapi patient permit enrol
fail trastuzumab site japan south korea taiwan nivolumab opdivo
studi piii trial attract patient fail
two line chemotherapi irrespect statu
advanc bladder cancer remain unaddress market
target therapi contrast gastric breast cancer agent
wide studi advanc bladder cancer even diseas
rather standard-of-car muscle-invas local advanc metastat
urotheli carcinoma irrespect statu cisplatin regimen
gemcitabin plu cisplatin year patient inelig platinum-bas
chemotherapi treatment checkpoint inhibitor recommend nccn
guidelin set multipl agent fda-approv
prefer treatment pembrolizumab keytruda altern nivolumab
opdivo atezolizumab tecentriq durvalumab imfinzi avelumab bavencio
nccn guidelin due pauciti trial investig therapi
unlik face direct competit agent would like
releg therapi failur
prototyp agent trastuzumab one first agent investig
treatment advanc bladder cancer open-label trial
conduct trastuzumab ad combo regimen cisplatin
gemcitabin paclitaxel tcgp inclus criteria allow entri patient
express detect gene amplif assay elev serum
total patient receiv tcgp regimen yield orr
compos cr pr median time progress
month os month treatment-rel advers event gener line
expect specifi chemo regimen though somewhat higher
rate cardiac toxic expect experienc grade event hussain et
al clin oncol howev initi promis result never translat
/iii random trial anoth studi single-ag trastuzumab
set termin prematur recruit difficulti
prior adopt agent standard-of-car piii trial examin use
lapatinib mainten therapi platinum-bas chemotherapi
page
pleas see import disclosur inform page report
patient progress diseas recal lapatinib dual inhibitor egfr
complet cycl chemotherapi patient random
receiv lapatinib placebo daili pre-plan analys conduct
primari secondari endpoint os respect patient stratifi
egfr score includ subgroup posit egfr
posit egfr posit
across subgroup addit mainten lapatinib confer signific benefit
likewis overal result non-signific overal median
month lapatinib vs month placebo hr overal os
month lapatinib vs month placebo hr powl et al
late-lin therapi bladder cancer heterogen numer target agent
play on-going clinic trial howev much opportun expect
segment mutat statu cancer posit certain mutat
elig treatment correspond target agent includ erlotinib
tarceva gefitinib iressa cetuximab erbitux panitumumab vectibix egfr
dovitinib cabozantinib cabometriq c-met
anti-angiogenesi agent target vegf bevacizumab avastin ramucirumab
cymraza aflibercept zaltrap sunitinib sutent broader applic
recent piii rang trial show improv month ad
ramucirumab docetaxel mo experiment arm vs mo standard care arm hr
patient progress platinum-bas chemotherapi small
number enrol patient elig chemo progress checkpoint
inhibitor addit orr improv addit ramucirumab
docetaxel almost doubl rate seen standard care experiment arm vs
standard care arm statist analysi conduct os matur petrylak
et al lancet given like approv ramucirumab similar gastric
cancer and/or set lack efficaci date would
posit direct competitor ramucirumab bladder cancer
advanc breast cancer present nich opportun late-lin
therapi locoregion recurr typic address surgic
resect /-radiat therapi system recurr de novo stage iv metastat
breast cancer patient candid endocrin and/or therapi
depend receptor express nccn guidelin diseas current
standard-of-car tripl combo pertuzumab trastuzumab docetaxel
paclitaxel note pertuzumab recent addit base result piii cleopatra
trial show increas os trial arm contain pertuzumab
docetaxel hr swain et al nejm patient progress
therapi nccn guidelin recommend antibodi drug conjug ado-
trastuzumab emtansin patient fail therapi nccn guidelin
recommend one addit line therapi plu chemo consid
palli care thu creat nich could address
decad combo trastuzumab plu taxan chemotherapi consid
standard-of-car therapi metastat breast cancer lapatinib plu
capecitabin use therapi progress trastuzumab
piii emilia trial random patient previous treat trastuzumab taxan
ado-trastuzumab emtansin lapatinib plu capecitabin studi arm receiv ado-
page
pleas see import disclosur inform page report
trastuzumab emtansin saw month increas os time second interim
analysi mo vs mo hr meet benefit threshold
stop trial earli verma et al nejm result ado-trastuzumab emtansin
prefer therapi releg lapatinib therapi compet
variou altern combin agent chemotherapi
therefor set logic entri point could like see
lapatinib-bas regimen compar arm pivot trial
despit progress trastuzumab continu blockad shown
benefici late-lin therapi metastat breast cancer therefor
numer combo regimen later therapi still includ trastuzumab plu
follow chemotherapi agent paclitaxel carboplatin vinorelbin
capecitabin trastuzumab may also use combin lapatinib without
addit chemo furthermor hormon receptor er/pr -posit diseas endocrin
therapi combin ether trastuzumab lapatinib pertuzumab also
found activ beyond set nccn plan updat guidanc
optim sequenc agent metastat breast cancer nccn
sever next-gener tyrosin kinas inhibitor tki recent approv
clinic develop breast cancer juli fda approv puma
biotechnolog cover neratinib nerlynx extend adjuv therapi
patient early-stag breast cancer follow trastuzumab
interim result present trial neratinib combin
capecitabin patient advanc breast cancer metastas
preliminari result promis surviv orr
respons defin volumetr decreas brain lesion
howev grade diarrhea experienc patient could
concern adopt late-lin therapi
anoth entrant late-lin therapi cascadian therapeut casc cover
pivot trial advanc breast cancer set
studi patient previous receiv pertuzumab-bas regimen ado-
trastuzumab emtansin random tripl combo tucatinib
trastuzumab capecitabin placebo trastuzumab capecitabin
os primari secondari endpoint respect addit tucatinib
assess two pib trial one combo ado-trastuzumab emtansin anoth
combo trastuzumab and/or capecitabin
us gastric cancer estim approxim address patient
advanc unresect stage iii/iv gastric cancer failur therapi trastuzumab
plu chemotherapi upon success clinic develop expect
enter us market therapi advanc gastric cancer
estim captur approxim market launch ramp
peak assum launch wholesal acquisit cost wac price
per month pariti pertuzumab dose along price increas
per year account patient complianc gross-to-net sale model us
peak sale risk-adjust appli risk discount gastric cancer
page
pleas see import disclosur inform page report
bladder cancer estim approxim address patient
advanc stage muscle-invas bladder cancer failur platinum-bas
chemotherapi therapi inhibitor follow success clinic
trial expect enter us market therapi
advanc bladder cancer estim captur approxim
market launch ramp peak assumpt launch wac price
dose frequenc price increas line valu state gastric cancer
adjust patient complianc gross-to-net sale model us peak sale
risk-adjust risk discount bladder cancer
breast cancer estim approxim address patient
metastat stage iv breast cancer failur pertuzumab plu trastuzumab plu
chemotherapi therapi ado-trastuzumab emtansin
follow
success clinic trial expect enter us market therapi
metastat breast cancer estim captur approxim
market launch ramp peak assumpt launch
wac price dose frequenc price increas line valu state gastric
bladder cancer adjust patient complianc gross-to-net sale
model us peak sale risk-adjust risk discount breast cancer
model us peak sale risk-adjust across indic
gastric bladder breast cancer addit
indic
uterine/endometri ovarian cancer includ valuat time
repres addit upsid estim
well-character oncogen overexpress varieti
cancer epiderm growth factor receptor also known
neu cell surfac receptor member larg epiderm growth factor receptor
egfr famili tyrosin kinas receptor exist monom direct
activ ligand instead becom activ dimer egfr famili
receptor bind wide rang growth factor molecul activ
receptor lead upregul prolif anti-apoptot signal pathway
includ mapk pkc overexpress known oncogen driver
directli contribut tumorigenesi amplif overexpress occur
varieti cancer breast gastric/gastroesophag bladder ovarian
endometrium lung colon head neck major research date
focus breast cancer set first target
therapi trastuzumab herceptin develop sinc advent
therapi overal surviv mani cancer significantli improv
serv predict biomark gutierrez schiff pathol lab
costimul recent adopt clinic strategi
enhanc anti-tumor immun respons sever molecul
function costimulatori immun receptor t-cell activ includ
glucocorticoid tnfr-relat protein gitr
member tumor necrosi factor tnf superfamili
one wide studi costimulatori molecul mainli express activ
t-cell lesser extent activ b-cell natur killer nk
cell t-cell activ bind ligand
known natur occur ligand constitut express antigen-pres
cell apc dendrit cell upon bind large-scal cluster
multipl receptor ligand induc trigger downstream signal note
page
pleas see import disclosur inform page report
